You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CME

Changing Paradigms in the Treatment of Severe Asthma: The Role of Biologic Therapies

  • Authors: Rohit Katial, MD; Bradley E. Chipps, MD; Monica Kraft, MD; and William W. Busse, MD
  • CME Released: 4/29/2016
  • THIS ACTIVITY HAS EXPIRED
  • Valid for credit through: 4/29/2017
Start Activity


Target Audience and Goal Statement

This activity is intended for allergists, pulmonologists, pediatricians, family practitioners, and other healthcare providers who treat patients with asthma.

The goal of this activity is to provide clinically relevant, evidence-based information to guide physicians as new biologics emerge for the treatment of severe asthma.

Upon completion of this activity, participants will be able to:

  1. Recognize the epidemiology and distinguishing characteristics of "difficult to treat" vs severe asthma
  2. Interpret current data on the role of eosinophils in the pathophysiology of severe asthma
  3. Distinguish the treatment approaches that are effective in patients with T helper 2 (TH2)-high versus TH2- low asthma
  4. Assess recent clinical data on the efficacy, safety and mechanisms of action of biologic drugs in asthma


Disclosures

National Jewish Health (NJH) and its officers, Board of Directors, faculty, employees, representatives, and other agents (collectively, NJH Parties) shall not be responsible in any capacity for, and do not warrant any content whatsoever, in any NJH publication or other product (in any medium), or the use or reliance on any such content, and expressly disclaim any and all liability for such content. All such responsibility for content and use of product solely rests with the authors or the advertisers, as the case may be.

By way of example, without limiting the foregoing, this disclaimer of liability applies to the accuracy, completeness, effectiveness, quality, appearance, ideas, or products, as the case may be, of or resulting from, any statements, references, articles, positions, claimed diagnosis, claimed possible treatments, services, or advertising, express or implied, contained in any NJH live meeting, publication, online course or other product.

Furthermore, the content should not be considered medical advice and is not intended to replace consultation with a qualified medical professional. Under no circumstances, including negligence, shall any of the NJH Parties be liable for any direct, indirect, incidental, special, or consequential damages, or lost profits that result from any of the foregoing, regardless of legal theory and whether or not claimant was advised of the possibility of such damages.

In accordance with the Accreditation Council for Continuing Medical Education requirements, National Jewish Health has a conflict of interest policy that requires faculty to disclose relevant financial relationships related to the content of their presentations/materials. Any potential conflicts are resolved so that presentations are evidence-based and scientifically balanced.


Authors

  • Rohit Katial, MD

    Director, Allergy and Clinical Immunology Fellowship; Professor Helen Wohlberg & Herman Lambert Chair in Pharmacokinetics, Division of Allergy and Clinical Immunology, Department of Medicine, National Jewish Health, Denver, Colorado

    Disclosures

    Disclosure: Rohit Katial, MD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: AstraZeneca Pharmaceuticals LP; Meda Pharmaceuticals, Inc.; Teva Pharmaceuticals USA
    Served as a speaker or a member of a speakers bureau for: Meda Pharmaceuticals, Inc.; Teva Pharmaceuticals USA

    Dr Katial does intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

    Dr Katial does intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

  • Bradley E. Chipps, MD

    Vice President, American College of Allergy, Asthma & Immunology; Medical Director, Capital Allergy & Respiratory Disease Center, Sacramento, California

    Disclosures

    Disclosure: Bradley E. Chipps, MD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: AstraZeneca Pharmaceuticals LP; Boehringer Ingelheim Pharmaceuticals, Inc.; Genentech, Inc.; Meda Pharmaceuticals, Inc.; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation
    Served as a speaker or a member of a speakers bureau for: AstraZeneca Pharmaceuticals LP; Boehringer Ingelheim Pharmaceuticals, Inc.; Genentech, Inc.; Meda Pharmaceuticals, Inc.; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation

    Dr Chipps does intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

    Dr Chipps does intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

  • Monica Kraft, MD

    Robert S. and Irene P. Flinn Professor of Medicine; Chair, Department of Medicine, University of Arizona Health Sciences Center, Tucson, Arizona

    Disclosures

    Disclosure: Monica Kraft, MD, has disclosed the following financial relationships:
    Served as an advisor or consultant for: AstraZeneca Pharmaceuticals LP; Genentech, Inc.; Teva Pharmaceuticals USA
    Served as an investigator for: Chiesi Pharmaceuticals, Inc.; Roche; Sanofi
    Received royalties from: Elsevier B.V.

    Dr Kraft does intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

    Dr Kraft does intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

  • William W. Busse, MD

    Professor of Medicine, Division of Allergy, Pulmonary and Critical Care Medicine, University of Wisconsin School of Medicine, Madison, Wisconsin

    Disclosures

    Disclosure: William W. Busse, MD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: 3M; Aerocrine; Astellas Pharma, Inc.; AstraZeneca Pharmaceuticals LP; Boehringer Ingelheim Pharmaceuticals, Inc.; Genentech, Inc.; GlaxoSmithKline; Novartis Pharmaceuticals Corporation; Roche; Sanofi; Teva Pharmaceuticals USA
    Served on data monitoring boards for: Boston Scientific Corporation; Circassia, Ltd.
    Served on study oversight committee for: ICON plc.

    Dr Busse does intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

    Dr Busse does intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Editors

  • Laura A. DuBois

    Scientific Director, Medscape, LLC

    Disclosures

    Disclosure: Laura DuBois has disclosed no relevant financial relationships.

  • Susan L. Smith, MN, PhD

    Lead Scientific Director, Medscape, LLC

    Disclosures

    Disclosure: Susan L. Smith, MN, PhD, has disclosed no relevant financial relationships

Content Reviewer

  • Robert Morris, PharmD

    Associate CME Clinical Director, Medscape, LLC

    Disclosures

    Disclosure: Robert Morris, PharmD, has disclosed no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewers have disclosed the following relevant financial relationships:

Andrea Harshman, MHA, CHCP, CMP-HC

Director, Office Professional Education National Jewish Health

No financial relationships to disclose.

Ronina Covar, MD

Associate Co-Director, The Cohen Family Asthma Institute Associate Professor Department of Pediatrics National Jewish Health

Investigator: AstraZeneca Pharmaceuticals LP; National Heart, Lung, and Blood Institute (NHLBI); and Roche
Publication Author/Consultant: GlaxoSmithKline


Accreditation Statements

    For Physicians

  • National Jewish Health is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    National Jewish Health designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credits™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or printed out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME

Changing Paradigms in the Treatment of Severe Asthma: The Role of Biologic Therapies

Authors: Rohit Katial, MD; Bradley E. Chipps, MD; Monica Kraft, MD; and William W. Busse, MDFaculty and Disclosures
THIS ACTIVITY HAS EXPIRED

CME Released: 4/29/2016

Valid for credit through: 4/29/2017

processing....

  • Print